Granulomatosis With Polyangiitis Insights & Trends

• GPA is a rare ANCA-associated vasculitis (AAV) characterized by necrotizing inflammation of small- to medium-sized blood vessels, often involving the upper and lower respiratory tracts and kidneys. It is associated with anti-neutrophil cytoplasmic antibodies (ANCA) and presents with a wide range of systemic manifestations.
• AAVs are rare autoimmune disorders characterized by necrotizing inflammation of small- to medium-sized blood vessels. They are classified into three main types: GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Renal involvement occurs in over 75% of patients. AAV is associated with PR3-ANCA (c-ANCA) and MPO-ANCA (p-ANCA). GPA affects approximately 3 per 100,000 people, according to the Vasculitis Foundation.
• Routine laboratory tests in GPA are nonspecific. Findings may include abnormal renal function tests and urinalysis in patients with kidney involvement, low-titer positive rheumatoid factor in approximately two-thirds of patients, and elevated inflammatory markers such as ESR and CRP.

Granulomatosis with Polyangiitis (GPA) Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of GPA: ~ USD XX million
• 2036 Projected Diagnosed Prevalent Cases of GPA: ~ USD XX million
• GPA Growth Rate (2026–2036): ~XX % CAGR

DelveInsight's ‘Granulomatosis with Polyangiitis (GPA) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the GPA, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Granulomatosis with Polyangiitis (GPA) Understanding and Diagnostic Algorithm

Granulomatosis with Polyangiitis (GPA) Overview and Diagnosis

GPA, formerly known as Wegener's granulomatosis, is a rare, systemic autoimmune disorder characterized by necrotizing inflammation of small- to medium-sized blood vessels and granuloma formation, primarily affecting the upper respiratory tract, lungs, and kidneys. GPA belongs to the group of AAV, with the majority of patients testing positive for proteinase 3 (PR3)-ANCA. The disease can present with a wide range of manifestations, including chronic sinusitis, nasal crusting or ulcers, cough, hemoptysis, pulmonary nodules, and rapidly progressive glomerulonephritis, potentially leading to irreversible organ damage if left untreated. Diagnosis is based on a combination of clinical presentation, ANCA serology, imaging studies, and histopathological confirmation through tissue biopsy when feasible. Early and accurate diagnosis is critical to initiating timely treatment, preventing disease progression, and reducing the risk of long-term organ impairment.

Further details are provided in the report...

Granulomatosis with Polyangiitis (GPA) Epidemiology

The Granulomatosis with Polyangiitis epidemiology segment offers a comprehensive overview of both historical and current patient populations, along with forecasted trends across the seven major markets (7MM). It helps identify the factors influencing past, present, and future epidemiological patterns through the analysis of published studies and insights from key opinion leaders. Additionally, this section of the Granulomatosis with Polyangiitis market report presents data on the diagnosed patient population, associated trends, and the assumptions used in developing the epidemiological forecasts.

Key Findings from Granulomatosis with Polyangiitis (GPA) Epidemiological Analysis and Forecast

• GPA is the most prevalent form of AAV, with an estimated annual incidence of approximately 10–20 cases per million population worldwide, although rates vary by geographic region.
• Among patients with GPA, upper respiratory tract involvement is the most common manifestation, affecting approximately 92% of patients, followed by lower respiratory tract involvement (~85%), renal involvement (~80%), musculoskeletal symptoms (~67%), ocular involvement (~52%), skin involvement (~46%), and peripheral nervous system involvement (~20%) over the disease course.
• PR3-ANCA-positive disease constitutes the largest serological subgroup of GPA, representing approximately three-quarters of diagnosed cases, whereas MPO-ANCA-positive and ANCA-negative disease account for considerably smaller patient populations.

Gain strategic intelligence on Granulomatosis with Polyangiitis future market growth, treatment advancements, patient dynamics, and competitive landscape.

Scope of the Granulomatosis with Polyangiitis Epidemiology Report

• The report covers a segment of an executive summary, a descriptive overview of GPA, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Granulomatosis with Polyangiitis Epidemiology Report Insights

• Granulomatosis with Polyangiitis (GPA) Patient Population Forecast

Granulomatosis with Polyangiitis Epidemiology Report Key Strengths

• Epidemiology based (epi based) Bottom up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs Granulomatosis with Polyangiitis Epidemiology Report

• What are the disease risks, burdens, and unmet needs of GPA? What will be the growth opportunities across the 7MM concerning the patient population with GPA?
• What is the historical and forecasted GPA patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy Granulomatosis with Polyangiitis Epidemiology Report

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.